1.
Factors explored in univariate analysis
| Endpoints | Variables |
| OS, overall survival; DFS, disease-free survival; LRC, locoregional control; RT, radiotherapy; EBRT, external beam radiotherapy; BRT, brachytherapy; FIGO, International Federation of Gynecology and Obstetrics; TAH, total abdominal hysterectomy; BSO, bilateral salpingo-oophorectomy; PUD, previous uterine disease; ULMS, uterine leiomyosarcoma. | |
| OS, DFS, LRC | Adjuvant RT (yes vs.no) |
| Adjuvant RT (EBRT vs.EBRT+BRT) | |
| FIGO stage (I vs.others) | |
| FIGO stage (I vs.II vs.III vs.IV) | |
| Type of surgery (TAH±BSO vs.Wertheim) | |
| Grading (grade 1 vs.other) | |
| Grading (grade 1 vs.2 vs.3 vs.unknown) | |
| Number of mitoses/field
(<5vs.5–9 vs.≥10 vs.unknown) |
|
| Vascular invasion (yes vs.no) | |
| Necrosis in the surgical specimen
(yes vs.no or unknown) |
|
| Median age
(<54 years oldvs.≥54 years old) |
|
| PUD (yes vs.no) | |
| Delivery (yes vs.no) | |
| Previous cancer (yes vs.no) | |
| Previous surgery on the uterus for any reason (yes vs.no) | |
| Adjuvant chemotherapy (yes vs.no) | |
| Tumor size (≤8 cm vs.>8 cm) | |
| Tumor size (known vs.unknown) | |
| Pregnancy (yes vs.no) | |
| Family history for ULMS (yes vs.no) | |
| Hormonal treatment (yes vs.no) | |
| Symptoms at diagnosis (yes vs.no) | |
| Site of the tumor (body vs.others) | |
| Acute toxicity (yes vs.no) | |
| Late toxicity (yes vs.no) | |